Pulse pressure and diabetes treatments: Blood pressure and pulse pressure difference among glucose lowering modality groups in type 2 diabetes. Issue 6 (February 2018)

• Record Type: Journal Article
• Authors: Alemi, Hamid; Khaloo, Pegah; Mansournia, Mohammad Ali; Rabizadeh, Soghra; Salehi, Salome Sadat; Mirmiranpour, Hossein; Meftah, Neda; Esteghamati, Alireza; Nakhjavani, Manouchehr
• Other Names: Kuwabara. Masanari section editor.
• Is Part Of: Medicine. Volume 97:Issue 6(2018)
• Publication Date: 2018-02
• Subjects: cardiovascular safety -- glibenclamide -- insulin -- metformin -- pulse pressure -- systolic and diastolic blood pressure -- type 2 diabetes mellitus; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000009791
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Abstract: Type 2 diabetes is associated with higher pulse pressure. In this study, we assessed and compared effects of classic diabetes treatments on pulse pressure (PP), systolic blood pressure (SBP), and diastolic blood pressure (DBP) in patients with type 2 diabetes. In a retrospective cohort study, 718 non-hypertensive patients with type 2 diabetes were selected and divided into 4 groups including metformin, insulin, glibenclamide+metformin, and metformin+insulin. They were followed for 4 consecutive visits lasting about 45.5 months. Effects of drug regimens on pulse and blood pressure over time were assessed separately and compared in regression models with generalized estimating equation method and were adjusted for age, duration of diabetes, sex, smoking, and body mass index (BMI). Studied groups had no significant change in PP, SBP, and DBP over time. No significant difference in PP and DBP among studied groups was observed (PP:P = 0.090; DBP:P = 0.063). Pairwise comparisons of PP, SBP, and DBP showed no statistically significant contrast between any 2 studied groups. Interactions of time and treatment were not different among groups. Our results demonstrate patients using metformin got higher PP and SBP over time. Averagely, pulse and blood pressure among groups were not different. Trends of variation in pulse and blood pressure were not different among studied diabetes treatments.